Welcome to LookChem.com Sign In|Join Free
  • or
Carbamic acid, [2-cyano-2-(3,4-dimethoxyphenyl)ethenyl]-, ethyl ester is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

18029-59-9

Post Buying Request

18029-59-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

18029-59-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 18029-59-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,8,0,2 and 9 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 18029-59:
(7*1)+(6*8)+(5*0)+(4*2)+(3*9)+(2*5)+(1*9)=109
109 % 10 = 9
So 18029-59-9 is a valid CAS Registry Number.

18029-59-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name [2-cyano-2-(3,4-dimethoxy-phenyl)-vinyl]-carbamic acid ethyl ester

1.2 Other means of identification

Product number -
Other names N-Homoveratronitrilo-(α)-methinyl-urethan

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:18029-59-9 SDS

18029-59-9Relevant academic research and scientific papers

SOS1 INHIBITORS

-

Paragraph 0214-0215, (2021/09/04)

The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the com

GFAT INHIBITORS

-

, (2010/02/09)

Compounds of formula (I) are provided as well as pharmaceutically acceptable salts and esters thereof, wherein the substituents are as disclosed in the specification. The compounds have utility for the treatment of type 2 diabetes mellitus.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 18029-59-9